<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="The American Journal of Pathology"><meta name="citation_title" content="The AMY Antigen Co-Occurs with A&#x003b2; and Follows Its Deposition in the Amyloid Plaques of Alzheimer&#x02019;s Disease and Down Syndrome"><meta name="citation_authors" content="Cynthia A. Lemere, Trelawney J. Grenfell, and  Dennis J. Selkoe"><meta name="citation_date" content="1999 July"><meta name="citation_issue" content="1"><meta name="citation_volume" content="155"><meta name="citation_firstpage" content="29"><meta name="citation_pdf_url" content="http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1866646&amp;blobtype=pdf"><meta name="citation_abstract_html_url" content="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1866646&amp;rendertype=abstract"><meta name="citation_fulltext_html_url" content="http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1866646"><meta name="citation_pmid" content="10393833"><meta name="DC.Title" content="The AMY Antigen Co-Occurs with A&#x003b2; and Follows Its Deposition in the Amyloid Plaques of Alzheimer&#x02019;s Disease and Down Syndrome"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="American Society for Investigative Pathology"><meta name="DC.Contributor" content="Cynthia A. Lemere"><meta name="DC.Contributor" content="Trelawney J. Grenfell"><meta name="DC.Contributor" content="Dennis J. Selkoe"><meta name="DC.Date" content="1999 July"><meta name="DC.Language" content="en"><link rel="stylesheet" href="corehtml/pmc/css/pmcstatic.css" type="text/css"><link rel="stylesheet" href="corehtml/pmc/css/pmcbase1.css" type="text/css"><link rel="stylesheet" href="corehtml/pmc/css/pmcbars-red.css" type="text/css"><link rel="stylesheet" href="corehtml/pmc/css/pmcbody1.css" type="text/css"><link rel="stylesheet" href="corehtml/pmc/css/pmcrefs1.css" type="text/css"><script type="text/javascript" src="corehtml/pmc/js/common.js"></script><script type="text/javascript">window.name="mainwindow";</script><link href="http://www.ncbi.nlm.nih.gov/corehtml/jsutils/css/tileshop_pmc.1/tileshop_pmc.1.css" type="text/css" rel="stylesheet"><script type="text/javascript" src="http://www.ncbi.nlm.nih.gov/corehtml/jsutils/utils.1.js"></script><script>utils.jsLoader.sBase = "http://www.ncbi.nlm.nih.gov/corehtml/jsutils/";</script><script type="text/javascript" src="http://www.ncbi.nlm.nih.gov/corehtml/jsutils/tileshop_pmc.1/tileshop_pmc.1.js"></script><script type="text/javascript" src="http://www.ncbi.nlm.nih.gov/corecgi/tileshop/tileshop_data_db.1.js"></script><title>The AMY Antigen Co-Occurs with A&#x003b2; and Follows Its Deposition in the Amyloid Plaques of Alzheimer&#x02019;s Disease and Down Syndrome</title></head><body class="pmc-body"><a id="top" name="top"></a><table cellpadding="0" cellspacing="0" width="100%" border="0"><tr valign="top"><td colspan="3"><table border="0" cellspacing="0" cellpadding="0" style="border-collapse: collapse;"><tr><td width="145" valign="top"><img src="corehtml/pmc/pmcgifs/pmc3_logo_v5.gif" border="0" usemap="#pmclogo" alt="pmc logo image"><map name="pmclogo"><area shape="rect" alt="Journal List" coords="65,52,137,67" href="fprender.fcgi"><area shape="rect" alt="Search" coords="7,52,52,67" href="redirect3.cgi?&amp;&amp;auth=0Pk-8-R2LGomJ0vpZHAIVrcb_kphxIdEZpP4COkSE&amp;reftype=other&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CLogo&amp;TO=Entrez%7CSearch%7CAll%20PMC&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pmc"><area shape="rect" alt="pmc logo image" coords="0,0,145,75" href="./"></map></td><td height="75" valign="top" style="padding-left: 4px;"><div><img align="top" border="0" src="corehtml/pmc/pmcgifs/logo-amjpathol.gif" alt="Logo of amjpathol" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area shape="rect" alt="American Journal of Pathology For Authors" coords="319,64,400,75" href="redirect3.cgi?&amp;&amp;auth=0buwKmqT9eJ2aPEr3XBBkDfMqHyQ9VfbqoNrcUk1X&amp;reftype=publisher&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN%2FA&amp;rendering-type=normal&amp;&amp;http://ajp.amjpathol.org//misc/ifora.shtml" target="pmc_ext" onclick="focuswin('pmc_ext')"><area shape="rect" alt="American Journal of Pathology Subscribe" coords="251,64,319,75" href="redirect3.cgi?&amp;&amp;auth=0FScjpMT_gzO5jN-NtXPY76UKElm7bFf6l8nuMQzW&amp;reftype=publisher&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN%2FA&amp;rendering-type=normal&amp;&amp;http://ajp.amjpathol.org//subscriptions/" target="pmc_ext" onclick="focuswin('pmc_ext')"><area shape="rect" alt="American Journal of Pathology Search" coords="192,64,250,75" href="redirect3.cgi?&amp;&amp;auth=0pWldq3RImvUlpR8ZRaa69QrMtRINB2Z7FYrXkAfk&amp;reftype=publisher&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN%2FA&amp;rendering-type=normal&amp;&amp;http://ajp.amjpathol.org//search.dtl" target="pmc_ext" onclick="focuswin('pmc_ext')"><area shape="rect" alt="American Journal of Pathology Current Issue" coords="108,64,192,75" href="redirect3.cgi?&amp;&amp;auth=08oBXxXAUOgJ0wbH-A9FBTEqlHy7lGJBfgQkjJAT3&amp;reftype=publisher&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN%2FA&amp;rendering-type=normal&amp;&amp;http://ajp.amjpathol.org//current.shtml" target="pmc_ext" onclick="focuswin('pmc_ext')"><area shape="rect" alt="American Journal of Pathology About the Journal" coords="0,64,108,75" href="redirect3.cgi?&amp;&amp;auth=06sx4V03arswVFVPCUdhFvRWdufSQYgIvxMpN2Q6H&amp;reftype=publisher&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN%2FA&amp;rendering-type=normal&amp;&amp;http://ajp.amjpathol.org//misc/about.shtml" target="pmc_ext" onclick="focuswin('pmc_ext')"><area shape="rect" alt="American Journal of Pathology" coords="0,0,399,62" href="redirect3.cgi?&amp;&amp;auth=0PqHuGsoV7VLUGEfD7bAYNkpJpQf2Gx_iZn9VoAmC&amp;reftype=publisher&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN%2FA&amp;rendering-type=normal&amp;&amp;http://ajp.amjpathol.org/" target="pmc_ext" onclick="focuswin('pmc_ext')"></map></div></td></tr></table></td></tr></table><table cellpadding="0" cellspacing="3" width="100%" border="0"><tr><td></td><td colspan="2"><div class="navlink-box navlink-box-gray"><a href="fprender.fcgi" class="navlink">Journal List</a><span> &gt; </span><a class="navlink" href="tocrender.fcgi?journal=338&amp;action=archive">Am J Pathol</a><span> &gt; </span><a class="navlink" href="tocrender.fcgi?iid=144111">v.155(1); Jul 1999</a></div></td></tr><tr><td width="145" valign="top" class="sidebar-cell"><div class="sidebar-article-navigation-box"><div class="sidefm-pmclink-item"><a href="articlerender.fcgi?artid=1866646&amp;rendertype=abstract" class="sidefm-pmclink">Abstract</a></div><div class="sidefm-pmccurrent-item"><a class="sidefm-pmclink" href="javascript:return(false);"><span class="sidebar-menu-square-image-holder"><img border="0" src="corehtml/pmc/pmcgifs/square.gif" alt="&gt;"></span>Full Text</a></div><div class="sidefm-pmclink-item"><a href="picrender.fcgi?artid=1866646&amp;blobtype=pdf" class="sidefm-pmclink">PDF (1.3M)</a></div><div class="sidefm-pmclink-item"><a href="tocrender.fcgi?iid=144111" class="sidefm-pmclink">Contents</a></div><div class="sidefm-pmclink-item"><a href="tocrender.fcgi?journal=338&amp;action=archive" class="sidefm-pmclink">Archive</a></div></div><div class="sidebar-pubmed-box"><div class="sidebar-pubmed-links-to-box"><form name="pubmedLinks" onsubmit="return pubMedDbLinkSubmit(this)"><div class="sidefm-pmsubhead"><label for="pubmedOption">Related material:</label></div><select name="pubmedOption" id="pubmedOption" class="sidefm-pmart" onchange="return pubMedDbLinkSubmit(this)"><option value="redirect3.cgi?&amp;&amp;auth=065Iq5MSFcAGeqS6Dgpx_K3Dvn13pRwMZLrIfd5T9&amp;reftype=abs&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article|Navigation&amp;TO=Entrez|PubMed|Record&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/10393833">PubMed record</option><option selected value="redirect3.cgi?&amp;&amp;auth=0bCdPAIVCbhxeINov-EHCm_HkKaWRtBJcMp-soQDl&amp;reftype=relart&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article|Navigation&amp;TO=Entrez|PubMed|Related%20Records&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&amp;cmd=Link&amp;dbFrom=PubMed&amp;from_uid=10393833">PubMed related arts</option><option value="redirect3.cgi?&amp;&amp;auth=0vw6sd5_cror-tVUjzwFcFdZK-MbZCNlBE6jWmkfo&amp;reftype=linkout&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article|Navigation&amp;TO=Entrez|PubMed|Linkout&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&amp;Cmd=ShowLinkOut&amp;TermToSearch=10393833">PubMed LinkOut</option><option value="redirect3.cgi?&amp;&amp;auth=0HcTyASNit81qMVjCTbat6sbd5pWPMLIp65KWV5zN&amp;reftype=Substance&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article|Navigation&amp;TO=Entrez|Crosslink|PubChem%20Substance&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pmc&amp;cmd=Display&amp;from_uid=1866646&amp;dopt=pmc_pcsubstance">Substance</option><option value="redirect3.cgi?&amp;&amp;auth=0PsNQsq29Qay31SifPhDiIh3u1TzFTiMU4gnF2QAa&amp;reftype=Taxonomy&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article|Navigation&amp;TO=Entrez|Crosslink|Taxonomy&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pmc&amp;cmd=Display&amp;from_uid=1866646&amp;dopt=pmc_taxonomy">Taxonomy</option><option value="redirect3.cgi?&amp;&amp;auth=0rwDk5GOL6Jd7-QApieumph4lWzcP_78gXDP_75WR&amp;reftype=Taxonomy&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article|Navigation&amp;TO=Entrez|Crosslink|Taxonomy&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?Db=taxonomy&amp;DbFrom=pmc&amp;cmd=Link&amp;LinkName=pmc_taxonomy&amp;doptcmdl=TxTree&amp;IdsFromResult=1866646">Taxonomy tree</option></select><br><input type="image" src="corehtml/pmc/pmcgifs/go.gif" alt="Go" class="sidefm-pmart"></form></div><div class="sidebar-pubmed-author-box"><div class="sidefm-pmsubhead">PubMed articles by:</div><div class="sidefm-pmclink-item"><a href="redirect3.cgi?&amp;&amp;auth=0xkdCdW4reafelR5Q1m1bUybJk1e7kLHxKKFZ7Qvj&amp;reftype=authsrch&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CNavigation&amp;TO=Entrez%7CPubMed%7CAuthor%20Search&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;db=PubMed&amp;term=%20Lemere+CA%5Bauth%5D" class="sidefm-pmclink"> Lemere, C.</a></div><div class="sidefm-pmclink-item"><a href="redirect3.cgi?&amp;&amp;auth=04mTjXmRF7j5icMczWlEpymgulZWleOej5NVykQpc&amp;reftype=authsrch&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CNavigation&amp;TO=Entrez%7CPubMed%7CAuthor%20Search&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;db=PubMed&amp;term=%20Grenfell+TJ%5Bauth%5D" class="sidefm-pmclink"> Grenfell, T.</a></div><div class="sidefm-pmclink-item"><a href="redirect3.cgi?&amp;&amp;auth=0pymx4lfIPJGD1ssSPdCZ5LuhkJI8iK53diXycQ6L&amp;reftype=authsrch&amp;refto=entrez&amp;reffrom=sidebar&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CNavigation&amp;TO=Entrez%7CPubMed%7CAuthor%20Search&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;db=PubMed&amp;term=%20Selkoe+DJ%5Bauth%5D" class="sidefm-pmclink"> Selkoe, D.</a></div></div></div></td><td rowspan="103" width="20px" height="300" background="corehtml/pmc/pmcgifs/wm-amjpathol.gif"><div style="width:20px"></div></td><td valign="top" class="content-cell"><div class="front-matter-section"><table cellspacing="0" cellpadding="0" width="100%"><tr style="vertical-align: top"><td><div class="fm-citation"><div><span class="citation-abbreviation">Am J Pathol. </span><span class="citation-publication-date">1999 July; </span><span class="citation-volume">155</span><span class="citation-issue">(1)</span><span class="citation-flpages">: 29–37. </span></div><div><span class="fm-vol-iss-date"> </span></div></div></td><td class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span>PMC1866646</div></td></tr></table><div class="fm-copyright"><a class="int-reflink" href="about/copyright.html">Copyright</a>  &#x000a9; 1999, American Society for Investigative Pathology</div><div class="fm-title">The AMY Antigen Co-Occurs with A&#x003b2; and Follows Its Deposition in the Amyloid Plaques of Alzheimer&#x02019;s Disease and Down Syndrome</div><div class="fm-author contrib-group">Cynthia A. Lemere, Trelawney J. Grenfell, and  Dennis J. Selkoe<div class="fm-affl">From the Center for Neurologic Diseases, Harvard Medical School and Brigham and Women&#x02019;s Hospital, Boston, Massachusetts</div></div><div class="fm-footnote"></div><div class="fm-pubdate">Accepted March 20, 1999.</div><div class="links-box"><div class="fm-footnote"><img src="corehtml/pmc/pmcgifs/rt-arrow.gif" alt="Small right arrow pointing to:" style="vertical-align: middle;"> This article has been <a class="int-reflink" href="tocrender.fcgi?artid=1866646&amp;action=cited">cited by</a> other articles in PMC.</div></div></div></td></tr><tr valign="top"><td class="sidebar-cell" width="145"><div class="side-section-group"><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#top" class="sidefm-pmclink" style="text-transform: none;">Top</a></div></span><div class="sidefm-pmccurrent-item"><a class="sidefm-pmclink" href="javascript:return(false);" style="text-transform: none;"><span class="sidebar-menu-square-image-holder"><img border="0" src="corehtml/pmc/pmcgifs/square.gif" alt="&gt;"></span>Abstract</a></div><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id465022" class="sidefm-pmclink" style="text-transform: none;">Materials and Methods</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id485760" class="sidefm-pmclink" style="text-transform: none;">Results</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id486060" class="sidefm-pmclink" style="text-transform: none;">Discussion</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id486287" class="sidefm-pmclink" style="text-transform: none;">References</a></div></span></div></td><td class="content-cell"><div class="head1 section-title" style="text-transform: none;" id="id449147">Abstract</div><div class="section-content"><!--article-meta-->Novel plaque-like &#x0201c;AMY&#x0201d; lesions were recently described in the brains of patients with Alzheimer&#x02019;s disease (AD). Using three A&#x003b2; antibodies, we now document the co-occurrence of AMY immunoreactivity (IR) with amyloid &#x003b2;-peptide (A&#x003b2;) in the large majority of plaques in AD brain. AMY IR was detected in many compacted plaques, whereas its co-localization with early, diffuse A&#x003b2; deposits was rare. AMY IR overlapped considerably or fully with A&#x003b2; and, in more severely affected AD brains, decorated the periphery of some plaques. In a temporal series of 29 Down syndrome (DS) brains from patients aged 12 to 73 years, the earliest AMY IR was detected in some plaques at age 15, following the earliest appearance of A&#x003b2; plaques (age 12 years), and then accrued within a subset of A&#x003b2; deposits, namely, the more spherical, compacted plaques. Brains from DS patients 29 years and older showed AMY staining in many A&#x003b2; plaques, as seen in AD. Brains from eight monkeys aged 17 to 34 years and thirty APP transgenic mice aged 8 to 20 months showed A&#x003b2; IR but no AMY IR. We conclude that AMY IR represents an amyloid-associated antigen that co-deposits in most but not all A&#x003b2; plaques in AD and DS and that accumulation of the AMY antigen follows A&#x003b2; deposition in plaques.</div></td></tr><tr valign="top"><td class="sidebar-cell" width="145"><div class="side-section-group"><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#top" class="sidefm-pmclink" style="text-transform: none;">Top</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id449147" class="sidefm-pmclink" style="text-transform: none;">Abstract</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id465022" class="sidefm-pmclink" style="text-transform: none;">Materials and Methods</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id485760" class="sidefm-pmclink" style="text-transform: none;">Results</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id486060" class="sidefm-pmclink" style="text-transform: none;">Discussion</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id486287" class="sidefm-pmclink" style="text-transform: none;">References</a></div></span></div></td><td class="content-cell"><div class="head1 section-title" style="text-transform: none;" id="id449163"> </div><div class="section-content">Alzheimer&#x02019;s disease (AD) is characterized neuropathologically by the presence of two principal brain lesions, amyloid plaques and neurofibrillary tangles. The earlier of the two lesions, the amyloid plaque, is formed by the progressive extracellular deposition in brain parenchyma of heterogeneous amyloid &#x003b2;-peptides (A&#x003b2;) proteolytically derived from the &#x003b2;-amyloid precursor protein (&#x003b2;APP).<sup><a href="#b1" class="cite-reflink bibr"> 1</a></sup>  Because the &#x003b2;APP gene is encoded on chromosome 21 and is overexpressed in trisomy 21 (Down syndrome (DS)), DS provides a temporal model for studying AD pathogenesis.<sup><a href="#b2" class="cite-reflink bibr"> 2-5</a></sup>  A&#x003b2; peptides ending at residue 42 (A&#x003b2;42), as opposed to the more abundantly produced A&#x003b2; peptides ending at residue 40 (A&#x003b2;40), have been shown to be the initially deposited species in AD and DS brain,<sup><a href="#b6" class="cite-reflink bibr"> 6,7</a></sup>  with the earliest deposits detected immunohistochemically in DS brain as diffuse plaques at 12 years.<sup><a href="#b5" class="cite-reflink bibr"> 5</a></sup>  In addition, other proteins have been found to associate with A&#x003b2; in AD plaques.<sup><a href="#b5" class="cite-reflink bibr"> 5, 8-14</a></sup>  The deposition of some A&#x003b2;-associated proteins may be indicative of a local inflammatory response to the amyloid, and the accrual of others may stabilize the A&#x003b2; or promote its aggregation.<p>Recently, abundant A&#x003b2;-negative AMY plaques were described immunohistochemically in AD brain.<sup><a href="#b15" class="cite-reflink bibr"> 15</a></sup>  A monoclonal antibody (MAb) used in that study, AMY 117, was raised against an as-yet-unidentified 100-kd protein present in paired-helical-filaments-tau-rich AD brain extracts. An accompanying commentary to this report raised the possibility that AMY plaques are a non-amyloid precursor to A&#x003b2;-bearing senile plaques.<sup><a href="#b16" class="cite-reflink bibr"> 16</a></sup>  In collaboration with the authors of the original report, we sought to determine the temporal sequence of deposition of the AMY 117 antigen relative to that of A&#x003b2;. The immunoreactivity (IR) of the AMY 117 MAb was compared with that of each of three A&#x003b2; antibodies in brains obtained from three temporal models of AD pathogenesis: DS patients (aged 12 to 73 years), monkeys (aged 17 to 34 years), and PD-APP transgenic mice (aged 8 to 20 months). The immunohistochemical protocols were first optimized for each antibody in AD brain sections for each of the fixation and embedding conditions used in these three temporal models of AD.</p></div></td></tr><tr valign="top"><td class="sidebar-cell" width="145"><div class="side-section-group"><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#top" class="sidefm-pmclink" style="text-transform: none;">Top</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id449147" class="sidefm-pmclink" style="text-transform: none;">Abstract</a></div></span><div class="sidefm-pmccurrent-item"><a class="sidefm-pmclink" href="javascript:return(false);" style="text-transform: none;"><span class="sidebar-menu-square-image-holder"><img border="0" src="corehtml/pmc/pmcgifs/square.gif" alt="&gt;"></span>Materials and Methods</a></div><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id485760" class="sidefm-pmclink" style="text-transform: none;">Results</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id486060" class="sidefm-pmclink" style="text-transform: none;">Discussion</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id486287" class="sidefm-pmclink" style="text-transform: none;">References</a></div></span></div></td><td class="content-cell"><div class="head1 section-title" style="text-transform: none;" id="id465022">Materials and Methods</div><div class="section-content"><p><div class="head2 head-separate">Subject Groups</div>Autopsied brains from 22 AD patients (aged 64 to 96 years; mean, 83 years) and 10 aged human controls (aged 60 to 87 years; mean, 78 years) were used to optimize immunostaining protocols for each tissue preparation and to characterize the spatial patterns of immunoreactivity (IR) of antibodies to A&#x003b2; or AMY. A series of 29 brains from clinically diagnosed DS patients (aged 12 to 73 years; mean, 38 years), the neuropathology of most of which has been previously described,<sup><a href="#b5" class="cite-reflink bibr"> 5</a></sup>  was examined to determine the temporal sequence of deposition of A&#x003b2; and AMY relative to each other. Within this series, brain tissues from 10 young DS cases (aged 12 to 29 years) were generously provided by Dr. K. Wisniewski (Institute for Basic Research in Developmental Disabilities, Staten Island, NY). In addition, brain sections from three young DS patients lacking AD pathology were kindly provided by Dr. D. Anthony (Department of Pathology, Harvard Medical School, Boston, MA). Brain tissues from the remaining 16 DS patients (aged 36 to 73 years) were collected at autopsy by us at Brigham and Women&#x02019;s Hospital. Brain tissues from two animal models of AD pathogenesis were also examined: eight monkeys (aged 17 to 34 years) and 30 PD-APP transgenic mice<sup><a href="#b17" class="cite-reflink bibr"> 17</a></sup>  aged 8 to 20 months (kindly provided by Athena Neurosciences, South San Francisco, CA).</p><p><div class="head2 head-separate">Tissue Preparation</div>Blocks of human and monkey brain tissues from cerebral cortex, hippocampus, and cerebellum were fixed in 10% neutral buffered formalin for three time intervals ranging from 1) 1 to 2 hours (AD, aged human controls, older DS (&#x0003e;29 years), and monkey brains; brief fixation) to 2) an unknown period longer than 1 week (duplicate blocks from AD, older DS, and monkey brains; routine fixation) to 3) several years (12- to 29-year-old DS brains; long-term fixation). For several AD, DS, and aged control brains, additional blocks were fixed in 70% ethanol in 125 mmol/L NaCl at 4&#x000b0;C for 2 days. PD-APP transgenic mice were saline perfused and their hemibrains immersion fixed in 70% ethanol in 125 mmol/L NaCl at 4&#x000b0;C for 1 to 2 days. Fixed brain tissue was dehydrated and embedded in paraffin. Eight-micron sections were baked at 58&#x000b0;C for 1 hour. In addition, fresh-frozen 6-&#x003bc;m cryostat sections were prepared for several subjects in each group (except the monkeys). Frozen sections were fixed with cold acetone before immunolabeling.</p><p><div class="head2 head-separate">Immunohistochemistry</div>Serial sections were immunostained with the avidin-biotin horseradish peroxidase/diaminobenzidine (DAB) method (rabbit or mouse ABC Elite kit, Vector Laboratories, Burlingame, CA), using the antibodies detailed below. Details of the immunostaining protocol have been previously described.<sup><a href="#b5" class="cite-reflink bibr"> 5</a></sup>  Double labeling was accomplished using the horseradish peroxidase/DAB kit to detect the first primary antibody and the alkaline phosphatase ABC kit with Vector Red substrate (Vector Laboratories) to detect the second primary antibody. All antibodies were tested on long-term, routinely and briefly fixed AD and DS paraffin sections as well as on frozen sections to determine optimal staining conditions. Our sensitive general A&#x003b2; antibody R1282 (1&#x0003a;1000),<sup><a href="#b18" class="cite-reflink bibr"> 18</a></sup>  which detects multiple A&#x003b2; forms, was used as a reference antibody for A&#x003b2; plaque distribution. A highly sensitive A&#x003b2;42-endspecific MAb, 21F12 (1&#x0003a;1000),<sup><a href="#b19" class="cite-reflink bibr"> 19</a></sup>  was used to detect early, diffuse plaques as well as more mature plaques (gift of Athena Neurosciences, South San Francisco, CA). In long-term and routinely formalin-fixed tissues, both A&#x003b2; antibodies required formic acid pretreatment (88% formic acid for 8 minutes at room temperature (RT)) to optimize visualization of A&#x003b2; deposits. AMY 117 hybridoma supernatant MAb (AMY 117; gift of Lee and Trojanowski Laboratories, The Center for Neurodegenerative Research, University of Pennsylvania School of Medicine, Philadelphia, PA)<sup><a href="#b15" class="cite-reflink bibr"> 15</a></sup>  was used neat on all tissues. AMY 117 ascites MAb (AMY 117<sub>asc</sub>; 1&#x0003a;5000; gift of Lee and Trojanowski Laboratories) was used in absorption experiments with A&#x003b2;1&#x02013;40 and A&#x003b2;1&#x02013;42 peptides (20 &#x003bc;g of A&#x003b2; peptide/1 &#x003bc;l of antibody) as well as to confirm AMY 117 staining. In long-term and routinely formalin-fixed tissues, the AMY 117 staining required a double pretreatment: antigen retrieval by microwaving the sections for 10 minutes in citrate buffer solution (BioGenex, San Ramon, CA) followed by proteinase K digestion (Dako Corp., Carpinteria, CA) for 6 minutes at RT. No pretreatment was required for AMY 117 immunostaining of briefly formalin-fixed or ethanol-fixed paraffin sections or on cryosections. The HistoMouse-SP kit (Zymed Laboratories, South San Francisco, CA), an immunohistochemistry kit designed to use MAbs on mouse sections, was used in conjunction with MAb AMY 117 on the PD-APP transgenic mouse brain sections so as to avoid cross-reactivity with endogenous mouse IgG. Selected sections from all subject groups were stained for amyloid deposits with thioflavin S.</p><p><div class="head2 head-separate">Microscopy</div>For light microscopy, photomicrographs were generated using an Olympus BX50 microscope. For the confocal image shown in Figure 1<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f1" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a> , kindly provided by Dr. M. L. Schmidt (The Center for Neurodegenerative Diseases, University of Pennsylvania School of Medicine, Philadelphia, PA), a polyclonal antibody raised against native A&#x003b2; purified from AD brain and made in our laboratory, Angela (1&#x0003a;250),<sup><a href="#b20" class="cite-reflink bibr"> 20</a></sup>  was used for double-immunofluorescent labeling of A&#x003b2; and AMY 117 on a 40-&#x003bc;m ethanol-fixed, cryoprotected AD brain section. Here, A&#x003b2; IR was visualized using a Texas-Red-conjugated donkey anti-rabbit secondary antibody (1&#x0003a;400; Jackson ImmunoResearch Laboratories, West Grove, PA) whereas AMY 117 IR was visualized using a fluorescein-isothiocyanate-conjugated donkey anti-mouse secondary antibody (1&#x0003a;100; Jackson ImmunoResearch Laboratories). A series of six confocal images were obtained through the section at 1-&#x003bc;m intervals using a Leica confocal laser scanning microscope, as previously described.<sup><a href="#b15" class="cite-reflink bibr"> 15</a></sup> <div style="margin: 1em; margin-right: 2em;        border: 1px solid #999999;border-left: 1px solid #AAAAAA;border-bottom: 1px solid #AAAAAA;"><div style="border: 3px solid #F0F0F0; border-left: 1px solid #F8F8F8; border-bottom: 1px solid #F8F8F8;"><a id="f1" name="f1"></a><table border="0" cellpadding="5" cellspacing="5" style="clear:both; width: 100%;"><tr valign="top" align="left"><td width="100" align="center"><a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f1" class="icon-reflink" onclick="startTarget(this, 'figure', 1024, 800)"><img src="picrender.fcgi?artid=1866646&amp;blobname=jh0791767001.gif" border="1" class="icon-reflink" alt="Figure 1." title="Figure 1."></a></td><td><a class="side-caption" href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f1" onclick="startTarget(this, 'figure', 1024, 800)"><strong>Figure 1.</strong></a><div class="figure-table-caption-in-article"><span>Immunostaining with antibodies to A&#x003b2; and AMY 117 demonstrated the co-occurrence of the two antigens in the vast majority of plaques in AD brain. <strong>a</strong> and <strong>b</strong>: Adjacent 8-&#x003bc;m ethanol-fixed, paraffin sections of occipital cortex from a 90-year-old</span><a class="side-caption" style="font-size: 100%;" href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f1" onclick="startTarget(this, 'figure', 1024, 800)"> (more ...)</a></div></td></tr></table></div></div><div style="clear:both;"></div></p></div></td></tr><tr valign="top"><td class="sidebar-cell" width="145"><div class="side-section-group"><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#top" class="sidefm-pmclink" style="text-transform: none;">Top</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id449147" class="sidefm-pmclink" style="text-transform: none;">Abstract</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id465022" class="sidefm-pmclink" style="text-transform: none;">Materials and Methods</a></div></span><div class="sidefm-pmccurrent-item"><a class="sidefm-pmclink" href="javascript:return(false);" style="text-transform: none;"><span class="sidebar-menu-square-image-holder"><img border="0" src="corehtml/pmc/pmcgifs/square.gif" alt="&gt;"></span>Results</a></div><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id486060" class="sidefm-pmclink" style="text-transform: none;">Discussion</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id486287" class="sidefm-pmclink" style="text-transform: none;">References</a></div></span></div></td><td class="content-cell"><div class="head1 section-title" style="text-transform: none;" id="id485760">Results</div><div class="section-content"><p><div class="head2 head-separate">AD and Older DS Brains</div>In both single-labeled adjacent sections and in double-labeled sections, the vast majority of AMY 117 immunoreactive plaques were co-localized to some degree with A&#x003b2; immunoreactivity (IR) detected by antibodies R1282 (a general A&#x003b2; polyclonal antibody) and 21F12 (A&#x003b2;42-specific MAb) in both AD and older (&#x02265;29 years) DS brains. AMY 117 IR was always restricted to those cortical and hippocampal regions that contained A&#x003b2; deposits. Many, but not all, AMY IR plaques overlapped with thioflavin-S-labeled amyloid plaques. As exemplified in Figure 1<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f1" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a> , AMY 117 IR frequently co-localized (eg, overlapped) with A&#x003b2; IR (Figure 1, a&#x02013;c)<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f1" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a> , was interspersed with it (Figure 1c)<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f1" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a> , or, in the more pathologically severe brains, surrounded it (Figure 1, d&#x02013;f)<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f1" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a>  within an individual plaque lesion. In the latter case, the two antigens were found to partially overlap or to segregate but abut each other. Subpial A&#x003b2; deposits, large diffuse A&#x003b2;42 IR bands, cerebellar A&#x003b2; deposits, and vessel wall A&#x003b2; were all devoid of any AMY 117 IR (see asterisks in Figure 1, d&#x02013;f<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f1" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a> ). Occasionally, small punctate AMY 117 immunoreactive deposits that did not appear to overlap with A&#x003b2; IR were observed; such deposits occurred only in brain regions bearing abundant A&#x003b2; IR plaques (see arrowheads in Figure 1, d and e<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f1" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a> ). However, the presence of both antigens could often be detected in these same lesions in sections just above or below the plane of the initially stained section (see arrowhead in Figure 1f<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f1" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a> ). Absorption of antibodies R1282 (A&#x003b2;) and AMY 117<sub>asc</sub> with synthetic A&#x003b2;1&#x02013;40 and A&#x003b2;1&#x02013;42 peptides caused ablation of plaque staining by R1282 (absorption with A&#x003b2;1&#x02013;40 peptide shown in Figure 2, a and b<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f2" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a> ) but did not diminish AMY 117 IR (Figure 2, c and d)<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f2" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a> . Figure 2<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f2" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a>  further illustrates the close co-occurrence of A&#x003b2; and AMY 117 within plaques, at both high and low magnification, in the brain of a 65-year-old DS patient. Regions of compacted A&#x003b2;42 IR plaques in hippocampus, parahippocampal gyrus, and temporal cortex were also AMY 117 IR, as shown at low magnification in Figure 2<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f2" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a>  (eg, small arrowheads in e and f). However, AMY 117 IR was absent in A&#x003b2;42 IR diffuse plaques in the parahippocampal gyrus (arrows in Figure 2, e and f<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f2" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a> ), in A&#x003b2;42 IR plaques in the subpial layers of temporal cortex (asterisks in Figure 2, e and f<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f2" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a> ), and in A&#x003b2;42 IR plaques in deep cortical layers and white matter (large arrowheads in Figure 2, e and f<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f2" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a> ) as judged in immediately adjacent sections. In AD and DS brains in general, A&#x003b2; IR, especially as detected with the A&#x003b2;42 MAb 21F12, was more abundant than AMY 117 IR.<div style="margin: 1em; margin-right: 2em;        border: 1px solid #999999;border-left: 1px solid #AAAAAA;border-bottom: 1px solid #AAAAAA;"><div style="border: 3px solid #F0F0F0; border-left: 1px solid #F8F8F8; border-bottom: 1px solid #F8F8F8;"><a id="f2" name="f2"></a><table border="0" cellpadding="5" cellspacing="5" style="clear:both; width: 100%;"><tr valign="top" align="left"><td width="100" align="center"><a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f2" class="icon-reflink" onclick="startTarget(this, 'figure', 1024, 800)"><img src="picrender.fcgi?artid=1866646&amp;blobname=jh0791767002.gif" border="1" class="icon-reflink" alt="Figure 2." title="Figure 2."></a></td><td><a class="side-caption" href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f2" onclick="startTarget(this, 'figure', 1024, 800)"><strong>Figure 2.</strong></a><div class="figure-table-caption-in-article"><span>AMY 117 IR was not diminished by pre-absorption with A&#x003b2; peptide and was less abundant than A&#x003b2;42 in old DS brain. <strong>a</strong> and <strong>b</strong>: Adjacent 8-&#x003bc;m briefly formalin-fixed, paraffin sections of hippocampus from a 65-year-old DS patient with</span><a class="side-caption" style="font-size: 100%;" href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f2" onclick="startTarget(this, 'figure', 1024, 800)"> (more ...)</a></div></td></tr></table></div></div><div style="clear:both;"></div></p><p><div class="head2 head-separate">Aged Human Control Brains</div>Of the 10 nondemented aged control brains examined, 2 had no A&#x003b2; or AMY 117 IR. In the remaining eight cases, varying amounts of A&#x003b2; deposition were detected in the cortex in each brain. Only three of the eight A&#x003b2;-bearing brains had any AMY 117 IR; A&#x003b2; IR was always much more abundant than that of AMY 117. In general, AMY 117 IR was associated with spherical, compacted plaques and plaques apparently undergoing compaction, but not with diffuse, thioflavin-negative plaques in these aged control brains (data not shown). As in AD brains, no vessel wall AMY 117 IR was detected, even when A&#x003b2; IR was present in the blood vessel.</p><p><div class="head2 head-separate">Down Syndrome Brains</div>To determine the relative temporal sequence of deposition of A&#x003b2; and the AMY 117 antigen, we immunolabeled adjacent sections of DS brains from patients ranging from 12 to 73 years old using the highly sensitive A&#x003b2;42 MAb 21F12 and the AMY 117 MAb. Frontal cortex sections from 13 young DS patients (aged 12 to 29 years) were examined; in addition, large sections containing both temporal cortex and hippocampus were available for three of these young DS cases and were immunostained with both antibodies. Because the young DS brains had been subjected to long-term fixation in formalin, various pretreatments were tested and then employed to allow visualization of the AMY 117 antigen. A combination pretreatment involving antigen retrieval by microwaving the section in a citrate buffer solution followed by a brief proteinase K digestion allowed the unmasking of the AMY 117 antigen in the long-term fixed tissues. A&#x003b2;42 plaque IR was observed in 7 of the 13 young DS brains (aged 12, 15, 16, 17, 21, 27, and 29 years) (exemplified in Figure 3, a, c, e, and g<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f3" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a> ). Quantitative analyses of A&#x003b2; deposition and other neuropathological characterization of these brains has been previously reported.<sup><a href="#b5" class="cite-reflink bibr"> 5</a></sup>  AMY 117 IR was detected in three of the seven young DS brains that had A&#x003b2; deposits (and in none of those that did not). Specifically, the frontal and temporal cortices and hippocampus of a 15-year-old DS patient having thioflavin-positive amyloid plaques and shown previously to have compacted and cored A&#x003b2; IR plaques, gliosis, and some neuritic changes had some AMY 117 IR plaques (not shown); the hippocampus of a 16-year-old DS patient that showed compacted A&#x003b2; IR plaques had some AMY 117 IR (Figure 3, e and f)<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f3" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a> , whereas the frontal and temporal cortices having only diffuse A&#x003b2;42 IR plaques did not (Figure 3, c and d)<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f3" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a> ; and the frontal cortex of a 29-year-old DS patient (Figure 3, g and h)<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f3" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a>  previously shown to have compacted and cored A&#x003b2; IR plaques, gliosis, and some neuritic changes had many plaques positive for both A&#x003b2; and AMY 117. In the brains of the four young DS patients (aged 12, 17, 21, and 27 years) that had almost exclusively diffuse A&#x003b2;42 IR plaques, AMY 117 IR was not detected (eg, Figure 3, a and b<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f3" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a> ). Brains from middle-aged and older DS patients showed AMY 117 IR very similar to that described above for AD, as demonstrated in the brain of a 65-year-old DS patient in Figure 2<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f2" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a> . As in AD cases, no vascular or cerebellar AMY 117 IR was detected in DS brains at any age, even though abundant A&#x003b2; deposition occurred in each structure in these older DS brains.<div style="margin: 1em; margin-right: 2em;        border: 1px solid #999999;border-left: 1px solid #AAAAAA;border-bottom: 1px solid #AAAAAA;"><div style="border: 3px solid #F0F0F0; border-left: 1px solid #F8F8F8; border-bottom: 1px solid #F8F8F8;"><a id="f3" name="f3"></a><table border="0" cellpadding="5" cellspacing="5" style="clear:both; width: 100%;"><tr valign="top" align="left"><td width="100" align="center"><a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f3" class="icon-reflink" onclick="startTarget(this, 'figure', 1024, 800)"><img src="picrender.fcgi?artid=1866646&amp;blobname=jh0791767003.gif" border="1" class="icon-reflink" alt="Figure 3." title="Figure 3."></a></td><td><a class="side-caption" href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f3" onclick="startTarget(this, 'figure', 1024, 800)"><strong>Figure 3.</strong></a><div class="figure-table-caption-in-article"><span>A&#x003b2;42 deposition precedes that of the AMY 117 antigen in young DS brain. Eight-micron, long-term formalin-fixed, paraffin sections from young DS brain were immunostained with A&#x003b2;42 antibody 21F12 and are shown in the left column (<strong>a, c, e,</strong></span><a class="side-caption" style="font-size: 100%;" href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f3" onclick="startTarget(this, 'figure', 1024, 800)"> (more ...)</a></div></td></tr></table></div></div><div style="clear:both;"></div></p><p><div class="head2 head-separate">Monkey Brains and PD-APP Transgenic Mouse Brains</div>To further characterize the temporal accrual of AMY 117 in A&#x003b2; plaque lesions, two animal models of AD pathogenesis were examined. Cortical sections bearing A&#x003b2; (R1282 and 21F12) immunoreactive plaques from the brains of eight monkeys ranging in age from 17 to 34 years were immunostained with the AMY 117 MAb. In addition, hemibrain sections from 30 A&#x003b2; (R1282) immunoreactive plaque-bearing PD-APP transgenic mice, aged 8 to 20 months, were examined for AMY 117 IR (using the HistoMouse kit (Zymed Laboratories, South San Francisco, CA) to avoid mouse IgG cross-reactivity). No AMY 117 IR was detected in any of these monkey or transgenic mouse brains, regardless of A&#x003b2; plaque deposition (data not shown). Even in the 18- and 20-month-old PD-APP transgenic mice that have very abundant compacted and cored A&#x003b2; IR and thioflavin-positive plaques, AMY 117 IR was not observed.</p></div></td></tr><tr valign="top"><td class="sidebar-cell" width="145"><div class="side-section-group"><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#top" class="sidefm-pmclink" style="text-transform: none;">Top</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id449147" class="sidefm-pmclink" style="text-transform: none;">Abstract</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id465022" class="sidefm-pmclink" style="text-transform: none;">Materials and Methods</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id485760" class="sidefm-pmclink" style="text-transform: none;">Results</a></div></span><div class="sidefm-pmccurrent-item"><a class="sidefm-pmclink" href="javascript:return(false);" style="text-transform: none;"><span class="sidebar-menu-square-image-holder"><img border="0" src="corehtml/pmc/pmcgifs/square.gif" alt="&gt;"></span>Discussion</a></div><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id486287" class="sidefm-pmclink" style="text-transform: none;">References</a></div></span></div></td><td class="content-cell"><div class="head1 section-title" style="text-transform: none;" id="id486060">Discussion</div><div class="section-content"><p>By optimizing the immunostaining protocols for the AMY 117 MAb and the A&#x003b2; antibodies on AD brain sections, we were able to document the clear co-occurrence of the AMY 117 and A&#x003b2; antigens within the vast majority of nondiffuse plaque lesions in AD cortex and hippocampus. The degree of AMY 117 IR within A&#x003b2; plaques varied from plaque to plaque, but importantly, the two antigens very frequently existed in the same lesion. AMY 117 IR was primarily associated with more rounded, compacted A&#x003b2; plaques, whereas its co-localization with large diffuse A&#x003b2; deposits was rare. The images in Figure 1<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f1" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a>  indicate that AMY 117 and A&#x003b2; can both co-mingle and specifically co-localize (eg, overlap) within an individual plaque. In a subset of more mature plaques, AMY 117 IR surrounds that of A&#x003b2;; in such cases, the two antigens may partially overlap or may segregate but abut each other. AMY 117 IR was not diminished by absorption of the antibody with A&#x003b2; peptide, suggesting that AMY 117 is a non-A&#x003b2; antigen. In general, the A&#x003b2; antigen was more abundant than the AMY 117 antigen in AD, aged human, and DS brains.</p><p>The discrepancy between our results and those reported earlier,<sup><a href="#b15" class="cite-reflink bibr"> 15</a></sup>  in which limited or sometimes no co-localization was described between AMY 117 and A&#x003b2; IR in AD brain sections, is probably due, in part, to differences in staining conditions. First, the pretreatments used in our study enhanced the A&#x003b2; IR, sometimes even in the ethanol-fixed sections, implying that some A&#x003b2; deposits may have been missed in the study by Schmidt et al.<sup><a href="#b15" class="cite-reflink bibr"> 15</a></sup>  Second, the A&#x003b2;42 MAb 21F12 and the A&#x003b2; polyclonal antibody R1282 are extremely sensitive at detecting multiple forms of A&#x003b2; deposits and, as such, allowed greatly increased detection of A&#x003b2; deposits relative to those detected by the polyclonal A&#x003b2; antibody 2332 used in the previous study.<sup><a href="#b15" class="cite-reflink bibr"> 15</a></sup>  Indeed, we have performed side-by-side comparisons of the three antibodies under the optimal staining conditions for each and have consistently found A&#x003b2;42 MAb 21F12 to detect the greatest number of A&#x003b2; deposits (C. A. Lemere and T. J. Grenfell, unpublished data). Our A&#x003b2; polyclonal antibody R1282 also detected more A&#x003b2; deposits than polyclonal antibody 2332 under optimal conditions but, in some cases, labeled fewer A&#x003b2; deposits relative to those stained by A&#x003b2;42 MAb 21F12. Third, in our study, we always single-labeled sections adjacent to the double-labeled sections so as to characterize the staining pattern for each antibody on its own to avoid the potential for steric competition between the antibodies for their respective antigens within lesions. Both in our hands, and recently in those of M. L. Schmidt (personal communication), a competition between A&#x003b2; and AMY 117 antibodies for their respective antigens in individual plaque lesions was observed and may explain why some AMY-positive plaques appeared to be A&#x003b2; negative in their study.</p><p>In full agreement with the earlier report, no AMY 117 IR was observed in A&#x003b2;-bearing blood vessels or in cerebellum, implying that there is a regional and cellular specificity for this protein to associate with A&#x003b2;. In our study, AMY 117 IR occurred only in those brain areas having A&#x003b2; immunoreactive plaques and never in regions devoid of A&#x003b2;. In contrast, low-magnification photomicrographs previously published by Schmidt and colleagues<sup><a href="#b15" class="cite-reflink bibr"> 15</a></sup>  (as shown in Figure 3<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f3" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a>  of their paper) illustrate an example of an AD case in which AMY 117 IR was detected in a region of parahippocampal gyrus devoid of A&#x003b2; using polyclonal antibody 2332. Upon request, the authors kindly provided us with several adjacent sections from the same block of tissue depicted in the figure. In our hands, the region previously described as being devoid of A&#x003b2; was A&#x003b2;42 plaque-rich using a different A&#x003b2; antibody (A&#x003b2;42 MAb 21F12) and pretreatment of the tissue with formic acid. Pretreatment of tissue and improved A&#x003b2; antibody sensitivity may account for the increased detection of A&#x003b2; deposits and, as such, the visualization of a much greater co-occurrence of A&#x003b2; with AMY 117 in the current study. Our conclusion is that regions of AMY IR are A&#x003b2;-rich. Careful inspection of Table 1 in the aforementioned paper confirms that in AD brain regions where both antigens were examined (positive staining listed as present (Y) or absent (N)), A&#x003b2; IR alone or A&#x003b2; and AMY 117 IR together were described, but not AMY 117 IR alone.<sup><a href="#b15" class="cite-reflink bibr"> 15</a></sup>  In the current study, small, punctate AMY 117 immunoreactive deposits that were not directly associated with A&#x003b2; IR were occasionally observed, but only in areas of abundant A&#x003b2; immunoreactive plaques. In general, these small, punctate AMY 117 deposits were located between and close to plaques and, as such, may represent the outer edge of a plaque that exists above or below the plane of the AMY-117-stained section, so that A&#x003b2; may be surrounded by the AMY 117 antigen (as we indeed observed in mature plaques (Figure 1, d&#x02013;f<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f1" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a> , arrows)) or the two antigens partially overlap (exemplified by Figure 1, d&#x02013;f<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f1" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a> , arrowheads).</p><p>By performing immunohistochemical studies of plaque development in a unique temporal series of 29 DS brains from patients between the ages of 12 and 73 years, we were able to determine that A&#x003b2; deposition clearly precedes that of the AMY 117 antigen. Early, diffuse A&#x003b2;42 plaques in young DS brains were AMY 117 negative; it was only after the appearance of more mature, compacted A&#x003b2; plaques that AMY 117 IR was observed. This point was best exemplified by the immunostaining of adjacent sections from a single block of brain tissue containing both temporal cortex and hippocampus from a 16-year-old DS patient (see Figure 3, c&#x02013;f<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f3" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a> ). Diffuse A&#x003b2;42 IR was detected throughout the temporal cortex, whereas more compacted A&#x003b2;42 IR plaques were seen in the hippocampus in the same section. In the adjacent section, AMY 117 IR was observed only in the more compacted plaques in the hippocampus; the temporal cortex in the same section was entirely AMY 117 negative. We cannot exclude the possibility that the AMY 117 antigen within diffuse plaques (but not compacted plaques) was destroyed by the harsh (long-term) fixation conditions or by the double pretreatment to expose antigens in the young DS brains. However, the lack of AMY 117 IR in the long-term-fixed young DS brains bearing exclusively diffuse A&#x003b2;42 IR is consistent with the lack of AMY 117 IR in diffuse A&#x003b2;42 IR deposits observed in briefly fixed tissues from middle-age and older DS patients (see Figure 2, e and f<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f2" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a> ) and in AD cases. Furthermore, the staining protocol for each antibody under each of the fixation conditions was optimized before use. Therefore, we believe it is very unlikely that technical factors could explain the lack of AMY 117 IR in the aforementioned young DS brains.</p><p>The pattern of AMY 117 IR seen in the young DS brains was also observed in briefly fixed aged human control brains in which only three of eight A&#x003b2;-bearing brains showed any AMY 117 IR, and then only in a small portion of all A&#x003b2; plaques. Again, it was the A&#x003b2; plaques that appeared to be in the process of compaction that showed AMY 117 IR. Neither AMY 117 nor A&#x003b2; IR were observed in two aged human control brains and in six young DS brains, lending further support to the conclusion that the AMY 117 antigen is not detectable in brain lesions before the appearance of A&#x003b2;.</p><p>Brains from two animal models of AD pathogenesis, aged monkey (17 to 24 years) and PD-APP transgenic mice (aged 8 to 20 months), were examined for A&#x003b2; and AMY 117 IR. A&#x003b2; IR deposits were observed in all of the monkey and mouse brains, and the number of A&#x003b2; deposits increased strikingly with age. AMY 117 IR was not detected in either species, regardless of A&#x003b2; plaque burden. The lack of AMY 117 IR in monkey and PD-APP transgenic mouse brain suggests two possibilities. First, a species difference in the AMY 117 antigen may make it unrecognizable by the human MAb. Second, insufficient maturation of the plaques in monkeys and transgenic mice, compared with that in AD brain, may be responsible for the lack of AMY 117 detection in the plaques of these animals.</p><p>In summary, we conclude that the AMY 117 antigen is a non-A&#x003b2; amyloid-associated protein that accrues in AD plaques after A&#x003b2; deposition, rather than existing as the subunit of a novel, A&#x003b2;-negative lesion in Alzheimer&#x02019;s disease. Because AMY 117 appears at the time of compaction of A&#x003b2; plaques, it may turn out to play a significant role in the evolution of the plaque. This new information is critical to the interpretation of AMY IR plaques in AD brain and to the further search for the AMY antigen.</p></div></td></tr><tr valign="top"><td class="sidebar-cell" width="145"> </td><td class="content-cell"><div class="head1 section-title" style="text-transform: none;" id="id486268">Acknowledgments</div><div class="section-content"><p><p>We are indebted to Dr. Marie Luise Schmidt (The Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA) for providing the confocal image shown in Figure 1<a href="articlerender.fcgi?artid=1866646&amp;rendertype=figure&amp;id=f1" class="fig-table-link " onclick="startTarget(this, 'figure', 1024, 800)"> <img src="corehtml/pmc/pmcents/rtrif.gif" border="0" alt="[triangle]" /></a>  and to Drs. Schmidt and John Trojanowski for many interesting and helpful discussions. In addition, we are grateful to Drs. Krystyna Wisniewski (Institute for Basic Research in Developmental Disabilities, Staten Island, NY) and Douglas Anthony (Department of Pathology, Harvard Medical School, Boston, MA) for generously providing brain tissues from young DS patients. Lastly, we thank Dr. Dora Games and Karen Khan for kindly providing fixed PD-APP transgenic mouse brains.</p></p></div></td></tr><tr valign="top"><td class="sidebar-cell" width="145"> </td><td class="content-cell"><div class="head1 section-title" style="text-transform: none;" id="footnotes">Footnotes</div><div class="section-content"><div class="fm-footnote"><div class="p"> Address reprint requests to: Dr. Cynthia A. Lemere, Center for Neurologic Diseases, Harvard Institutes of Medicine Room 622, 77 Avenue Louis Pasteur, Boston, MA 02115. E-mail: <span class="e_id486998">lemere/at/cnd.bwh.harvard.edu.</span><script type="text/javascript" language="JavaScript"><!--
                                    try{initUnObscureEmail ("e_id486998", '<a class="ext-reflink" href="' + reverseAndReplaceString('.ude.dravrah.hwb.dnc/ta/eremel:otliam', '/at/', '@') + '">' + reverseAndReplaceString('.ude.dravrah.hwb.dnc/ta/eremel', '/at/','@') + '</a>')}catch(e){}
                                //--></script></div></div><div class="fm-footnote"><div class="p">Supported by NIH grant (AG06173).</div></div></div></td></tr><tr valign="top"><td class="sidebar-cell" width="145"><div class="side-section-group"><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#top" class="sidefm-pmclink" style="text-transform: none;">Top</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id449147" class="sidefm-pmclink" style="text-transform: none;">Abstract</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id465022" class="sidefm-pmclink" style="text-transform: none;">Materials and Methods</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id485760" class="sidefm-pmclink" style="text-transform: none;">Results</a></div></span><span style="text-transform: none;"><div class="sidefm-pmclink-item"><a href="#id486060" class="sidefm-pmclink" style="text-transform: none;">Discussion</a></div></span><div class="sidefm-pmccurrent-item"><a class="sidefm-pmclink" href="javascript:return(false);" style="text-transform: none;"><span class="sidebar-menu-square-image-holder"><img border="0" src="corehtml/pmc/pmcgifs/square.gif" alt="&gt;"></span>References</a></div></div></td><td class="content-cell"><div class="head1 section-title" style="text-transform: none;" id="id486287">References</div><div class="section-content"><div class="back-matter-section"><div class="ref-cit-blk" id="b1"><div class="ref-label">1.</div><div class="ref-cit">Selkoe DJ: Amyloid &#x003b2;-protein and the genetics of Alzheimer&#x02019;s disease. <span class="ref-journal">J Biol Chem</span> 1996, <span class="ref-vol">271</span>:18295-18298  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0VopoAxCjOf0WQSIQeVFLME1d4IrP_w6wQS3Kf51j&amp;reftype=pubmed&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/8756120">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="b2"><div class="ref-label">2.</div><div class="ref-cit">Wisniewski K, Wisniewski H, Wen G: Occurrence of neuropathological changes and dementia of Alzheimer&#x02019;s disease in Down&#x02019;s syndrome. <span class="ref-journal">Ann Neurol</span> 1985, <span class="ref-vol">17</span>:278-282  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0TYfuwqH9TL0TphlqmX-1NuOtSII4k6Zscx70CAEQ&amp;reftype=pubmed&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/3158266">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="b3"><div class="ref-label">3.</div><div class="ref-cit">Rumble B, Retallack R, Hilbich C, Simms G, Multhaup G, Martins R, Hockey A, Montgomery P, Beyreuther K, Masters CL: Amyloid A4 protein and its precursor in Down&#x02019;s syndrome and Alzheimer&#x02019;s disease. <span class="ref-journal">N Engl J Med</span> 1989, <span class="ref-vol">320</span>:1446-1452  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0NKsk2rdOKQm1DE-2KS4AMCWgP6JfLA6sKAEDA5tk&amp;reftype=pubmed&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/2566117">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="b4"><div class="ref-label">4.</div><div class="ref-cit">Mann DMA, Brown A, Prinja D, Davies CA, Landon M, Masters CL, Beyreuther K: An analysis of the morphology of senile plaques in Down&#x02019;s syndrome patients of different ages using immunocytochemical and lectin histochemical techniques. <span class="ref-journal">Neuropathol Appl Neurobiol</span> 1989, <span class="ref-vol">15</span>:317-329  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0pGG9rWC3lm8erl4nc0q6qq2uUT1LuBElqDw-pQxJ&amp;reftype=pubmed&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/2528701">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="b5"><div class="ref-label">5.</div><div class="ref-cit">Lemere CA, Blustzjan JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ: Sequence of deposition of heterogeneous amyloid &#x003b2;-peptides and Apo E in Down syndrome: implications for initial events in amyloid plaque formation. <span class="ref-journal">Neurobiol Dis</span> 1996, <span class="ref-vol">3</span>:16-32  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=025bI_AonSIY9rDz2RnXzDpk2doFPV5_d78rdZATU&amp;reftype=pubmed&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/9173910">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="b6"><div class="ref-label">6.</div><div class="ref-cit">Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina H, Ihara Y: Visualization of A&#x003b2;42(43) and A&#x003b2;40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A&#x003b2;42(43). <span class="ref-journal">Neuron</span> 1994, <span class="ref-vol">13</span>:45-53  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0RUCu7Cp1Sl7wZhNgj8NwFJ_aZHjZABY-KsUPpkOF&amp;reftype=pubmed&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/8043280">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="b7"><div class="ref-label">7.</div><div class="ref-cit">Iwatsubo T, Mann DM, Odaka A, Suzuki N, Ihara Y: Amyloid &#x003b2; protein (A&#x003b2;) deposition: A&#x003b2;42(43) precedes A&#x003b2;40 in Down syndrome. <span class="ref-journal">Ann Neurol</span> 1995, <span class="ref-vol">37</span>:294-299  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0RwVaMOcxYeBjGyqm6YA5mV-IhAMrJ2ANK8ZKwQqK&amp;reftype=pubmed&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/7695229">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="b8"><div class="ref-label">8.</div><div class="ref-cit">Dickson DW: The pathogenesis of senile plaques. <span class="ref-journal">J Neuropathol Exp Neurol</span> 1997, <span class="ref-vol">56</span>:321-339  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=04gS66o6NpFd6ptJMnLTTwMI1IDNwShJAM4B6_A3O&amp;reftype=pubmed&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/9100663">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="b9"><div class="ref-label">9.</div><div class="ref-cit">Abraham CR, Selkoe DJ, Potter H: Immunochemical identification of the serine protease inhibitor, &#x003b1;<sub>1</sub>-antichymotrypsin in the brain amyloid deposits of Alzheimer&#x02019;s disease. <span class="ref-journal">Cell</span> 1988, <span class="ref-vol">52</span>:487-501  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0nC46F6ZlHBWaB0WSNtcvS21UOl-tZ8zMRGcNpkP-&amp;reftype=pubmed&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/3257719">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="b10"><div class="ref-label">10.</div><div class="ref-cit">Ma J, Yee A, Brewer HB, Jr, Das S, Potter H: Amyloid-associated proteins &#x003b1;1-antichymotrypsin and apolipoprotein E promote the assembly of the Alzheimer &#x003b2;-protein into filaments. <span class="ref-journal">Nature</span> 1994, <span class="ref-vol">372</span>:92-94  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0R5gSH_PnyRsuHkSH3FbWtJVQnhLAmw8Uc41AtAPC&amp;reftype=pubmed&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/7969426">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="b11"><div class="ref-label">11.</div><div class="ref-cit">Eikelenboom P, Hack CE, Rozemuller JM, Stam FC: Complement activation in amyloid plaques in Alzheimer&#x02019;s dementia. <span class="ref-journal">Virchows Arch B Cell Pathol</span> 1989, <span class="ref-vol">56</span>:259-262.</div></div><div class="ref-cit-blk" id="b12"><div class="ref-label">12.</div><div class="ref-cit">Eikelenboom P, Stam FC: Immunoglobulins and complement factors in senile plaques: an immunoperoxidase study. <span class="ref-journal">Acta Neuropathol</span> 1982, <span class="ref-vol">57</span>:239-242  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0P3L3-Du7RDT4VAN-thLBw6suB58rWniw2OkowAwX&amp;reftype=pubmed&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/6812382">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="b13"><div class="ref-label">13.</div><div class="ref-cit">Rogers J, Webster S, Lue L-F, Brachova L, Civin WH, Emmerling M, Shivers B, Walker D, McGeer P: Inflammation and Alzheimer&#x02019;s disease pathogenesis. <span class="ref-journal">Neurobiol Aging</span> 1996, <span class="ref-vol">17</span>:681-686  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0bANMVGfy6CDCZAzLIHE9EssYlxTytYxTz4FqoQkT&amp;reftype=pubmed&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/8892340">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="b14"><div class="ref-label">14.</div><div class="ref-cit">Zhan S-S, Veerhuis R, Kamphorst W, Eikelenboom P: Distribution of beta amyloid associated proteins in plaques in Alzheimer&#x02019;s disease and in the non-demented elderly. <span class="ref-journal">Neurodegeneration</span> 1995, <span class="ref-vol">4</span>:291-297  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0xET7CNjI3qf9eqlXf5tyKB0yP23W1WGlrWgTk5Cb&amp;reftype=pubmed&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/8581561">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="b15"><div class="ref-label">15.</div><div class="ref-cit">Schmidt ML, Lee VM-Y, Forman M, Chiu T-S, Trojanowski JQ: Monoclonal antibodies to a 100-kd protein reveal abundant A&#x003b2;-negative plaques throughout gray matter of Alzheimer&#x02019;s disease brains. <span class="ref-journal">Am J Pathol</span> 1997, <span class="ref-vol">151</span>:69-80  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0zSgiLXuiWwp-oko1w-tV6eGQN_t0Hh4VSacXcAYV&amp;reftype=pubmed&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/9212733">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="b16"><div class="ref-label">16.</div><div class="ref-cit">Dickson DW: Discovery of new lesions in neurodegenerative diseases with monoclonal antibody techniques. Is there a non-amyloid precursor to senile plaques? <span class="ref-journal">Am J Pathol</span> 1997, <span class="ref-vol">151</span>:7-11  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0xy2HkfHn6Jcmv4DCJb-cxwxZ1E3-MDo1-kYalQqF&amp;reftype=pubmed&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/9212725">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="b17"><div class="ref-label">17.</div><div class="ref-cit">Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, Gillespie F, Guido T, Hagopian S, Johnson-Wood K, Khan K, Lee M, Leibowitz P, Lieberburg I, Little S, Masliah E, McConlogue L, Montoya-Zavala M, Mucke L, Paganini L, Penniman E, Power M, Schenk D, Seubert P, Snyder B, Soriano F, Tan H, Vitale J, Wadsworth S, Wolozin B, Zhai J: Alzheimer-type neuropathology in transgenic mice overexpressing V717F &#x003b2;-amyloid precursor protein. <span class="ref-journal">Nature</span> 1995, <span class="ref-vol">373</span>:523-527  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0vuzZyhTnNwbMwZ1E0g9bvxunhbtZgqEop0lDWAfD&amp;reftype=pubmed&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/7845465">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="b18"><div class="ref-label">18.</div><div class="ref-cit">Haass C, Schlossmacher MG, Hung AY, Vigo-Pelfrey C, Mellon A, Ostaszewski BL, Lieberburg I, Koo EH, Schenk D, Teplow DB, Selkoe DJ: Amyloid &#x003b2;-peptide is produced by cultured cells during normal metabolism. <span class="ref-journal">Nature</span> 1992b, <span class="ref-vol">359</span>:322-325  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0XIqZUCfHGjBgJ4aVKbG_NDc399ds1Qi4M1vR1A-L&amp;reftype=pubmed&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/1383826">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="b19"><div class="ref-label">19.</div><div class="ref-cit">Johnson-Wood K, Lee M, Motter R, Hu K, Gordon G, Barbour R, Khan K, Gordon M, Tan H, Games D, Lieberburg I, Schenk D, Seubert P, McConlogue L: Amyloid precursor protein processing and A&#x003b2;42 deposition in a transgenic mouse model of Alzheimer&#x02019;s disease. <span class="ref-journal">Proc Natl Acad Sci USA</span> 1997, <span class="ref-vol">94</span>:1550-1555  <span style="white-space: nowrap;">[<a class="ref-extlink" href="redirect3.cgi?&amp;&amp;auth=0nMQfxlhenxdyzFjQ-Dcq8ie6Tm_ZPhWvF2-9gk2o&amp;reftype=pubmed&amp;artid=1866646&amp;article-id=1866646&amp;iid=144111&amp;issue-id=144111&amp;jid=338&amp;journal-id=338&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal&amp;&amp;http://www.ncbi.nlm.nih.gov/pubmed/9037091">PubMed</a>]</span>.</div></div><div class="ref-cit-blk" id="b20"><div class="ref-label">20.</div><div class="ref-cit">Selkoe DJ, Abraham CR, Podlisny MB, Duffy LK: Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer&#x02019;s disease. <span class="ref-journal">J Neurochem</span> 1986, <span class="ref-vol">146</span>:1820-1834.</div></div></div></div></td></tr><tr><td></td><td class="content-cell"><div class="footer-section"><hr><div class="sans90" style="margin: 0em 1em 1em; text-align: center;">Articles from <span class="acknowledgment-journal-title">The American Journal of Pathology</span> are provided here courtesy of <br><b>American Society for Investigative Pathology</b></div>
      <div class="footer-link" id="fp-footer">
        <div>
          <a class="link" href="mailto:pubmedcentral@nih.gov">Write to PMC</a>
           | 
          <a class="link" href="./">PMC Home</a>
           | 
          <a class="link" href="http://www.ncbi.nlm.nih.gov/pubmed">PubMed</a>
        </div>
        <div>
          <a class="link" href="http://www.ncbi.nlm.nih.gov">NCBI</a>
           | 
          <a class="link" href="http://www.nlm.nih.gov">U.S. National Library of Medicine</a>
        </div>
        <div>
          <a class="link" href="http://www.nih.gov">NIH</a>
           | 
          <a class="link" href="http://www.hhs.gov/">Department of Health and Human Services</a>
        </div>
        <div>
          <a class="link" href="about/privacypolicy.html">Privacy Policy</a>
           | 
          <a class="link" href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html">Disclaimer</a>
           | 
          <a class="link" href="http://www.nih.gov/icd/od/foia/index.htm">Freedom of Information Act</a>
        </div>
      </div>
    </div></td></tr></table></body></html><!--host:ipmc1-->

